Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surrozen (Nasdaq: SRZN) priced an underwritten common stock offering expected to raise $60 million in gross proceeds for the company.
The offering comprises 1,894,540 shares at $31.67 per share, all sold by Surrozen. Gross proceeds exclude underwriting discounts, commissions and offering expenses. The company expects closing on or about November 16, 2026, subject to customary closing conditions. Participants include Access Biotechnology, Boxer Capital Management, Perceptive Advisors, RTW Investments and Venrock Healthcare Capital Partners.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Underwritten offering is expected to raise $60 million in gross proceeds for Surrozen. 11% of market cap
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Issuance of 1,894,540 common shares at $31.67 per share dilutes existing holders.
News Explained
At the third-quarter 2026 operating-cash-use rate, the expected $60 million gross proceeds equal 1,143.3 days of use, before offering costs.
The offering is priced but not yet closed, with closing expected on or about
The effective S-3 shelf permits later registered sales without a new registration each time; it authorizes capacity but does not itself sell shares, while this offering is being made under it.
Sources and calculations
- Surrozen offering pricing release (2026-11-13)
- Dilution definition (2026-07-17)
- Form S-3 purpose (2026-07-17)
- Surrozen third-quarter 2026 operating cash flow (2026Q3)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $60,000,000 / ($4,828,000 / 92) = 1143.3 days
Key Figures
- Shares offered
- 1,894,540 shares
- Common stock sold by Surrozen
- Offering price
- $31.67 per share
- Underwritten offering
- Expected gross proceeds
- $60 million
- Before underwriting discounts, commissions and offering expenses
- Expected closing
- On or about November 16, 2026
- Subject to customary closing conditions
Key Terms
underwritten offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the pricing of an underwritten offering of 1,894,540 shares of its common stock at an offering price of
The offering includes participation from Access Biotechnology, Boxer Capital Management, Perceptive Advisors, RTW Investments, Venrock Healthcare Capital Partners, and other new and existing life sciences focused investors.
Morgan Stanley, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294542) that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on March 23, 2026 and was declared effective by the SEC on March 30, 2026. This offering is being made only by means of a prospectus supplement to be filed with the SEC and an accompanying prospectus that form a part of the effective registration statement. When available, copies of the prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimsecurities.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022; email: prospectus@cantor.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the completion of the offering. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the uncertainties related to the satisfaction of customary closing conditions for the offering, and all other factors discussed in the prospectus supplement and accompanying prospectus, Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 23, 2026 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 9, 2026, under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.
Investor and Media Contact:
Investorinfo@surrozen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.